REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 23, 2020 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced it will present at the following